Statements in which the resource exists.
SubjectPredicateObjectContext
dailymed-drugs:1213rdf:typehttp://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:1213rdf:typedailymed-instance:drugslld:dailymed
dailymed-drugs:1213rdfs:labelADVAIR DISKUS (Powder)lld:dailymed
dailymed-drugs:1213dailymed-instance:activeIng...dailymed-ingredient:FLUTICA...lld:dailymed
dailymed-drugs:1213dailymed-instance:boxedWarn...WARNING: RISK OF ASTHMA-RELATED DEATH: Long-acting beta-adrenergic agonists, such as salmeterol, one of the active ingredients in ADVAIR DISKUS, may increase the risk of asthma-related death. Therefore, when treating patients with asthma, physicians should only prescribe ADVAIR DISKUS for patients not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies. Data from a large placebo-controlled US study that compared the safety of salmeterol (SEREVENT' Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,176 patients treated for28 weeks on salmeterol versus 3 deaths out of 13,179 patients on placebo) [see Warnings and Precautions (5.1)].lld:dailymed
dailymed-drugs:1213dailymed-instance:activeMoi...dailymed-ingredient:FLUTICA...lld:dailymed
dailymed-drugs:1213dailymed-instance:inactiveI...dailymed-ingredient:LACTOSElld:dailymed
dailymed-drugs:1213dailymed-instance:genericMe...fluticasone propionate and salmeterollld:dailymed
dailymed-drugs:1213dailymed-instance:fullNameADVAIR DISKUS (Powder)lld:dailymed
dailymed-drugs:1213dailymed-instance:represent...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:1213dailymed-instance:routeOfAd...http://www4.wiwiss.fu-berli...lld:dailymed
dailymed-drugs:1213dailymed-instance:nameADVAIR DISKUSlld:dailymed
http://www4.wiwiss.fu-berli...dailymed-instance:producesD...dailymed-drugs:1213lld:dailymed